Gradient Therapeutics

Gradient Therapeutics is developing a novel, trans-vascular, catheter-based technology based on proven human clinical data in order to treat pulmonary hypertension, a fatal condition that affects approximately 500,000 patients per year worldwide. This disruptive therapy results in a reduction in pulmonary vascular resistance and improvement in cardiovascular hemodynamics, symptoms, and costs of care. The company has shown breakthrough potential as a life-saving treatment.